HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauder Q1: Firm Discusses China Tariff Uncertainties, Imminent Clinique Customization Launch

This article was originally published in The Rose Sheet

Executive Summary

The firm is confident that prestige beauty demand in China will remain a constant, translating to double-digit growth over the long term, but it’s taking a prudent approach to guidance in light of possible tariff impacts, among other unknowns. Lauder’s first-quarter sales totaled $3.52bn, up 11% in organic terms.

You may also be interested in...



Lauder Investing In Americas Turnaround While Asia/Pacific Continues To Soar

Prestige skin care continues to win big with young Chinese consumers, and makeup demand is picking up, according to Lauder leadership. Overall, the firm’s Asia/Pacific sales climbed 17%, reported, to $1.02bn, helping to offset continued declines in the Americas.

L’Oreal: 2018 Nine-Month Results Clearly Show ‘It’s Not The End Of The Big Brands’

Luxury beauty growth shows no signs of slowing, and L’Oreal markets some heavy hitters in the luxury tier. But L’Oreal Paris, Maybelline and other big names within the firm’s Consumer division also are having a superb year, with one noted exception.

Cosmetics Industry, Consumers Will Lose Under Latest Tariff Proposal In US-China Feud

The Personal Care Products Council says US-proposed tariffs on an additional $200bn of Chinese products, including a wide range of cosmetics and vital materials, will undermine American companies’ competitiveness and pass costs along to consumers. The group’s Executive VP-Global Strategies Francine Lamoriello testified on the matter in an Aug. 23 public hearing held by the US Trade Representative.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel